Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Serotonin

Generic Name: Serotonin

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂N_₂O

CAS Number: 50-67-9

Unique Ingredient Identifier: 333DO1RDJY

Overview

For temporary relief of nervousness, anxiety, mood swings, joint pains, weakness, drowsiness, itching and lethargy. Not evaluated by the FDA, homeopathic product.

Background

For temporary relief of nervousness, anxiety, mood swings, joint pains, weakness, drowsiness, itching and lethargy. Not evaluated by the FDA, homeopathic product.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Efficacy of Eye Movement Desensitization and Reprocessing (EMDR) Therapy Versus Selective Serotonin Reuptake Inhibitors (SSRIs) in the Treatment of Post-Traumatic Stress Disorder

Not Applicable

Recruiting

Posted: 2025/05/02

Sponsor:

Asad Ullah Jan

ID:NCT06955845

Trazodone on NREM Sleep Stage Ⅲ in Depressed Insomniac Co-morbid Patients

Phase 4

Recruiting

Posted: 2024/12/18

Sponsor:

Tongji University

ID:NCT06740188

Effectiveness of Dry Needling Adjuvant to Selective Serotonin Reputake Inhibitors vs TP Injection for Pain Management

Not Applicable

Active, not recruiting

Posted: 2024/06/13

Sponsor:Superior University

ID:NCT06457581

Hyaluronic Acid Injection in the Glans Penis Versus Selective Serotonin Reuptake Inhibitors for Lifelong Premature

Not Applicable

Completed

Posted: 2024/06/11

Sponsor:New Valley Universit...

ID:NCT06451406

Effect of Physiotherapy Protocol in Treatment of Depression: Longitudinal Study

Not Applicable

Not yet recruiting

Posted: 2023/03/27

Sponsor:Cairo University

ID:NCT05786677

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

UCLA Study Reveals SSRIs May Enhance Immune Response Against Cancer

2 days ago

UCLA researchers discovered that selective serotonin reuptake inhibitors (SSRIs) can enhance T cells' ability to fight cancer, reducing tumor size by more than half in multiple cancer models.

FDA Approves Brekiya: First DHE Autoinjector for Acute Migraine and Cluster Headache Treatment

9 days ago

The FDA has approved Amneal Pharmaceuticals' Brekiya, the first and only dihydroergotamine (DHE) autoinjector for acute treatment of migraine and cluster headaches in adults.

Fremanezumab Shows Dual Efficacy in Treating Both Migraine and Depression in Landmark Trial

18 days ago

A groundbreaking clinical trial demonstrates that fremanezumab, a CGRP-targeting monoclonal antibody, significantly reduces both migraine frequency and depressive symptoms in patients with comorbid conditions.

Tavapadon Shows Promise in Phase 3 Trials for Parkinson's Disease with Improved Motor Function and Safety Profile

a month ago

The TEMPO-1 and TEMPO-2 trials demonstrated that tavapadon, a selective D1/D5 dopamine receptor agonist, significantly improved motor function in newly diagnosed Parkinson's disease patients compared to placebo.

Vanda Pharmaceuticals Submits NDA for Novel Antipsychotic Bysanti to Treat Bipolar I Disorder and Schizophrenia

2 months ago

Vanda Pharmaceuticals has submitted a New Drug Application to the FDA for Bysanti (milsaperidone), seeking approval for the treatment of acute bipolar I disorder and schizophrenia.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy